Literature DB >> 8311549

Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study.

H Kröger1, R Honkanen, S Saarikoski, E Alhava.   

Abstract

OBJECTIVES: Although periarticular osteoporosis is a well-recognised phenomenon in rheumatoid arthritis (RA), there is considerable controversy over whether RA is associated with more generalised osteoporosis. The aetiology of this bone loss is probably multifactorial, including both life-style risk factors and disease-related determinants. Population-based studies on bone mineral density (BMD) in RA have not previously been conducted, and the purpose of the present cross-sectional population-based study was to determine whether patients with RA are at an increased risk of having osteoporosis. Furthermore, the determinants of BMD in RA patients were investigated.
METHODS: BMD at the spine and femoral neck was measured in 143 women with RA. The control group consisted of 1611 women with no disease or taking any drugs known to affect bone metabolism. The study population was a random stratified sample from the Kuopio Osteoporosis Study, which included all perimenopausal women aged 47-56 years residing in Kuopio Province, Eastern Finland in 1989 (n = 14,220). The mean age of the patients at the time of densitometry was 53.7 years.
RESULTS: The mean (SD) spinal and femoral neck BMD was significantly lower in patients with RA compared with controls [spine: 1.067 (0.161) v 1.129 (0.157) g/cm2, p < 0.001; femoral neck: 0.851 (0.136) v 0.932 (0.123) g/cm2, p < 0.001]. Analysis of variance showed that at the spine the difference was significant only in patients having corticosteroid treatment, whereas at the femoral neck patients with non-steroid treatment also had significantly lower BMD. When confounding factors were corrected, no significant difference could be found between non-steroid and corticosteroid treated patients with RA, suggesting that the independent effect of corticosteroids on BMD is only minimal. Multiple regression analysis found age, weight and functional grade to be significant predictors of spinal BMD (R2 = 0.403, p < 0.001). In the femoral neck weight, cumulative corticosteroid dose and functional grade were significant predictors of BMD (R2 = 0.410, p < 0.001).
CONCLUSIONS: RA is associated with generalised osteoporosis. The physical impairment and body weight are the major determinants of both spinal and femoral bone mass in RA patients. The cumulative corticosteroid dose was also a significant determinant of femoral neck BMD. However, the independent effect of corticosteroids is questionable because the use of corticosteroids may be an indicator of more severe disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8311549      PMCID: PMC1005237          DOI: 10.1136/ard.53.1.18

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  Bone mineral density measured by dual-energy X-ray absorptiometry in normal men.

Authors:  H Kröger; K Laitinen
Journal:  Eur J Clin Invest       Date:  1992-07       Impact factor: 4.686

2.  Determinants of total body and regional bone mineral density in normal postmenopausal women--a key role for fat mass.

Authors:  I R Reid; R Ames; M C Evans; S Sharpe; G Gamble; J T France; T M Lim; T F Cundy
Journal:  J Clin Endocrinol Metab       Date:  1992-07       Impact factor: 5.958

3.  Fractures after rheumatoid arthritis. A population-based study.

Authors:  J R Hooyman; L J Melton; A M Nelson; W M O'Fallon; B L Riggs
Journal:  Arthritis Rheum       Date:  1984-12

4.  Age-, sex-, and menopause-related changes of vertebral and peripheral bone: population study using dual and single photon absorptiometry and radiogrammetry.

Authors:  P Geusens; J Dequeker; A Verstraeten; J Nijs
Journal:  J Nucl Med       Date:  1986-10       Impact factor: 10.057

5.  Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women--the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study.

Authors:  M Tuppurainen; R Honkanen; H Kröger; S Saarikoski; E Alhava
Journal:  Maturitas       Date:  1993-09       Impact factor: 4.342

6.  Bone loss in rheumatoid arthritis and primary generalized osteoarthrosis: effects of corticosteroids, suppressive antirheumatic drugs and calcium supplements.

Authors:  D M Reid; N S Kennedy; M A Smith; J Nicoll; N Brown; P Tothill; G Nuki
Journal:  Br J Rheumatol       Date:  1986-08

7.  Bone turnover in early rheumatoid arthritis. 2. Longitudinal bone density studies.

Authors:  P N Sambrook; B M Ansell; S Foster; J M Gumpel; R Hesp; J Reeve
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

8.  Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis?

Authors:  O S Als; A Gotfredsen; B J Riis; C Christiansen
Journal:  Ann Rheum Dis       Date:  1985-06       Impact factor: 19.103

9.  The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state.

Authors:  O S Als; A Gotfredsen; C Christiansen
Journal:  Arthritis Rheum       Date:  1985-04

10.  Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity.

Authors:  R F Laan; W C Buijs; A L Verbeek; M P Draad; F H Corstens; L B van de Putte; P L van Riel
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

View more
  37 in total

Review 1.  Glucocorticoid-induced osteoporosis.

Authors:  P Boulos; G Ioannidis; J D Adachi
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 2.  Bone health and back pain: what do we know and where should we go?

Authors:  A M Briggs; L M Straker; J D Wark
Journal:  Osteoporos Int       Date:  2008-08-21       Impact factor: 4.507

3.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  Bone mineral density in patients with familial Mediterranean fever.

Authors:  Kadir Yildirim; Saliha Karatay; Ramazan Cetinkaya; Hulya Uzkeser; Akin Erdal; Ilyas Capoglu; Fazile Hatipoglu Erdem
Journal:  Rheumatol Int       Date:  2009-05-16       Impact factor: 2.631

5.  Sustained maintenance of exercise induced muscle strength gains and normal bone mineral density in patients with early rheumatoid arthritis: a 5 year follow up.

Authors:  A Häkkinen; T Sokka; H Kautiainen; A Kotaniemi; P Hannonen
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

6.  The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid.

Authors:  Tadashi Okano; Tatsuya Koike; Masahiro Tada; Yuko Sugioka; Kenji Mamoto; Shigeyuki Wakitani; Hiroaki Nakamura
Journal:  J Bone Miner Metab       Date:  2014-09       Impact factor: 2.626

Review 7.  [Bone densitometry in inflammatory rheumatic diseases : Characteristics of the measurement site and disease-specific factors].

Authors:  H Franck; J Braun; F Buttgereit; W Demary; G Hein; J Kekow; G Schett; P M Kern
Journal:  Z Rheumatol       Date:  2009-12       Impact factor: 1.372

8.  The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.

Authors:  Funda Tascioglu; Cengiz Oner; Onur Armagan
Journal:  Rheumatol Int       Date:  2003-03-21       Impact factor: 2.631

9.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.